DrugPatentWatch Database Preview

JADENU SPRINKLE Drug Profile

« Back to Dashboard

When do Jadenu Sprinkle patents expire, and when can generic versions of Jadenu Sprinkle launch?

Jadenu Sprinkle is a drug marketed by Novartis Pharms Corp and is included in one NDA. There is one patent protecting this drug.

This drug has forty-eight patent family members in thirty-four countries.

The generic ingredient in JADENU SPRINKLE is deferasirox. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferasirox profile page.

Summary for JADENU SPRINKLE

International Patents:	48
US Patents:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	40
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for JADENU SPRINKLE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JADENU SPRINKLE
DailyMed Link:	JADENU SPRINKLE at DailyMed

Synonyms for JADENU SPRINKLE

1044764-54-6

1133425-75-8

201530-41-8

4-((3E,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid

4-((3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid

4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid

4-[(3E,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid

4-[(3Z,5E)-3,5-Bis(6-Oxo-2,4-cyclohexadien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid, AldrichCPR

4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid

4-[3,5-bis(2-hydroxyphenyl)

4-[3,5-Bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid

4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid

4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid

4-[3,5-bis(6-oxidanylidenecyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid

4-[3,5-bis(6-oxo-1-cyclohexa-2,4-dienylidene)-1,2,4-triazolidin-1-yl]benzoic acid

4-{5-[(1E)-6-OXOCYCLOHEXA-2,4-DIEN-1-YLIDENE]-3-[(1Z)-6-OXOCYCLOHEXA-2,4-DIEN-1-YLIDENE]-1,2,4-TRIAZOLIDIN-1-YL}BENZOIC ACID

530D418

A814288

AB0020007

AB0073018

AB01565800_02

AB1008603

AC-8972

AC1NUU0E

AC1O1JMP

ACM1133425758

AKOS015855839

AKOS015902587

AKOS025312553

AN-5418

BC677677

BCP9000594

BDBM50088376

Benzoic acid, 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)-

Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-

BOFQWVMAQOTZIW-UHFFFAOYSA-N

C21H15N3O4

CAS-201530-41-8

CGP-72670

CHEBI:49005

CHEMBL550348

CS-0901

CTK8F0690

D03669

D0Q5UQ

DB01609

Deferasirox

Deferasirox (Exjade)

Deferasirox (JAN/USAN/INN)

Deferasirox [USAN:INN:JAN]

Deferasirox [USAN:INN]

Deferasirox-d4

Deferasirox, ICL670

Deferasiroxum

Deferasiroxum [INN-Latin]

DR002074

DSSTox_CID_28522

DSSTox_GSID_48596

DSSTox_RID_82794

DTXSID1048596

Exjade

Exjade (TN)

F0001-2380

FT-0601564

HE297142

HE323479

HMS3655A04

HSDB 7844

HY-17359

I14-1968

ICL 670

ICL 670A

ICL-670

ICL-670A

ICL670

ICL670A

J-013060

Jadenu

Jadenu (TN)

KB-49640

KE-0220

KS-00000G02

LS-186571

LS-187785

MFCD09751362

MFCD09951804

MLS003915634

MLS006010080

MolPort-006-392-553

MolPort-028-744-623

NCGC00181754-01

NCGC00263572-01

PubChem20503

s1712

SCHEMBL1071867

SCHEMBL61756

SCHEMBL62042

SMR002544689

SR-01000931971

SR-01000931971-2

Tox21_112926

Tox21_112926_1

UNII-V8G4MOF2V9

V0697

V8G4MOF2V9

W-5422

ZINC100022643

ZINC100504305

ZINC100504309

ZINC1481815

ZINC14880008

US Patents and Regulatory Information for JADENU SPRINKLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms Corp	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-001	May 18, 2017		RX	Yes	No			Y	Y
Novartis Pharms Corp	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-002	May 18, 2017		RX	Yes	No			Y	Y
Novartis Pharms Corp	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-003	May 18, 2017		RX	Yes	Yes			Y	Y

International Patents for JADENU SPRINKLE

Country	Document Number	Estimated Expiration
African Intellectual Property Organization (OAPI)	10946
Hungary	9903111
Germany	122007000020
European Patent Office	0914118

Supplementary Protection Certificates for JADENU SPRINKLE

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0248	Netherlands		300248, 20170624, EXPIRES: 20210827
C/GB07/002	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021.
2007001,C0914118	Lithuania		PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828
C 035/2006	Ireland		SPC 035/2006: 20070528, EXPIRES: 20210827